Harriet Kluger, MD
Yale University · Professor of Medicine · Yale New Haven Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Harriet Kluger, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:07 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07027488 · AB821 in Adult Participants With Locally Advanced or Metastatic Solid TumorsYale University · recruiting · Advanced Melanoma and Normal or Impaired, Advanced Melanoma · principal investigator
- Ph2NCT06521762 · Etrasimod for Immune Checkpoint Inhibitor Diarrhea and ColitisYale University · withdrawn · Immune Checkpoint Inhibitor-Related Diarrhea and Colitis · principal investigator
- Ph2NCT04955743 · Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaYale University · terminated · Melanoma, Renal Cell Carcinoma, Brain Metastases · principal investigator
- Ph1NCT04495257 · A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)Yale University · completed · Advanced Melanoma, Renal Cell Carcinoma · principal investigator
- Ph1NCT03502330 · APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaYale University · completed · Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma · principal investigator
- Ph2NCT02230306 · Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain MetastasesMelissa Burgess, MD · terminated · Active Melanoma Brain Metastases · principal investigator
- Ph2NCT02085070 · MK-3475 in Melanoma and NSCLC Patients With Brain MetastasesYale University · completed · Melanoma, Non-Small Cell Lung Cancer, Brain Metastases · principal investigator
- Ph1/Ph2NCT01350401 · Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic MelanomaAdaptimmune · terminated · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 3. Overcoming Melanoma Treatment Resistance with Cytokine ImmunotherapyP50CA121974 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · fiscal years 2006 to 2026Named on NCT03502330
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.